A Critical Review on the Long-Term COVID-19 Impacts on Patients With Diabetes - 27/04/24
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
The world is currently grappling with the potentially life-threatening coronavirus disease 2019 (COVID-19), marking it as the most severe health crisis in the modern era. COVID-19 has led to a pandemic, with the World Health Organization (WHO) predicting that individuals with diabetes are at a higher risk of contracting the virus compared to the general population. This review aims to provide a practical summary of the long-term impacts of COVID-19 on patients with diabetes. Specifically, it focuses on the effects of SARS-CoV-2 on different types of diabetic patients, the associated mortality rate, the underlying mechanisms, related complications, and the role of vitamin D and zinc in therapeutic and preventive approaches.
Methods |
Relevant literature was identified through searches on PubMed, Web of Science, and Science Direct in English, up to April 2023.
Results |
COVID-19 can lead to distressing symptoms and pose a significant challenge for individuals living with diabetes. Older individuals and those with pre-existing conditions such as diabetes, coronary illness, and asthma are more susceptible to COVID-19 infection. Managing COVID-19 in individuals with diabetes presents challenges, as it not only complicates the fight against the infection but also potentially prolongs the recovery time. Moreover, the virus may thrive in individuals with high blood glucose levels. Various therapeutic approaches, including antidiabetic drugs, are available to help prevent COVID-19 in diabetic patients.
Conclusions |
Diabetes increases the morbidity and mortality risk for patients with COVID-19. Efforts are globally underway to explore therapeutic interventions aimed at reducing the impact of diabetes on COVID-19.
Le texte complet de cet article est disponible en PDF.Keywords : Long-term COVID-19, Diabetes mellitus, Morbidity, Mortality, Treatment
Abbreviation : ACE, ALI, AMPK, APC, ARB, ARDS, CAP, CFR, CI, CLP, COPD, COVID-19, COX-2, CQ, DCGI, DIC, DM, DPP-4, ERK1/2, EuDKA, FEV1, FVC, GLP-1, hCoV-EMC, HCQ, HR, HUVEC, IDF, IQR, LKB1, MERS-CoV, mTOR, OR, PAI-1, PPE, RAAS, RdRP, ROS, RR, SARS-CoV-2, SGLT-2, T1D, T2D, TMPRSS2, TNF, TZD, VDR
Plan
| Funding: No funds, grants, or other support was received. |
|
| Conflicts of Interest: The authors declare no competing interest. Authors are primarily involved in education or medical research and not directly supported by the government. |
|
| Authorship: SA: Writing – original draft, Supervision, Investigation, Conceptualization. NM: Writing – review & editing. AG: Writing – review & editing, Resources. SG: Writing – review & editing. AF: Writing – review & editing, Resources. SR: Writing – original draft, Resources, Investigation. GG: Writing – original draft, Resources, Investigation. KD: Writing – original draft, Resources, Investigation. KRP: Writing – review & editing, Resources, Investigation. FT-H: Writing – review & editing, Supervision. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.